Alzheimer’s disease is an irreversible, chronic brain disorder that slowly affects a patient’s ability to remember and think. The disease (also referred to as "Alzheimer's") is named after German psychiatrist and neuropathologist Dr. Alois Alzheimer, whose pioneering research in the early 1900's advanced our understanding of the disorder. In the United States, the disorder is ranked as the sixth leading cause of death by the Centers for Disease Control and Prevention (CDC). A recent study published by the American Academy of Neurology suggests that it may rank third for patients older than 75, after heart disease and cancer.
Alzheimer’s is a degenerative disorder that results in loss of brain cells, and impairment of cognitive abilities severe enough to render the patient incapable of performing daily tasks. The most common early symptoms of the disorder are short-term memory loss, and a progressive decline in thinking, social and behavioral skills. The symptoms worsen with time, typically becoming serious enough to interfere with the patient’s daily life and affect his ability to function independently.
Alzheimer's accounts for roughly 60% to 80% of reported cases of dementia, broadly classified as impairments to behavior, thinking, and memory caused by brain injuries or disease. The disorder typically progresses from mild, to moderate, to severe phases over a period of time ranging from 5 to 15 years.
In the mild (or early) stage, patients typically face challenges with recalling basic facts and navigating previously familiar directions. Individuals with moderate (or middle) Alzheimer's exhibit increased anger, an inability to retain information such as their address, and have difficulties with basic hygiene and grooming. Finally, when the disease has progressed to the severe (or late) stage, patients must contend with extreme limitations in mobility, coherent speech, and facial expressions. In this state, those afflicted with the disorder must depend entirely on others for even the most routine of daily life activities.
Alzheimer’s is a complex disease, for which there is currently no cure. Current approaches include behavioral therapy and medications such as memantine and cholinesterase inhibitors. These solutions assist in managing behavioral impairments and memory loss caused by Alzheimer's. The impact, however, is temporary and (in the case of medication) accompanied by significant side effects. Researchers are working to deepen understanding of the disorder, and ultimately identify an effective treatment.
GIOSTAR (Global Institute of Stem Cell Therapy and Research) is home to the top experts in the field of stem cell research, and provides scientific know-how to GIOSTAR-CHICAGO. GIOSTAR-CHICAGO is an independently run facility from GIOSTAR. Involved in the field of stem cell research for almost two decades in the U.S.A, GIOSTAR has provided treatments to thousands of patients using their advanced protocols outside of the United States. GIOSTAR believes in the potential of supplementing traditional treatments for Alzheimer's disease (such as behavioral therapies and medications) with cellular rejuvenation therapy. Focusing solely on one particular form of treatment does not necessarily yield the desired results.
GIOSTAR opened the world’s first stem cell therapy hospital in India, and has plans to continue building stem cell treatment centers with health care partners around the world. Their goal is to develop treatments for several diseases, and offer hope to millions suffering around the globe with safe, effective and affordable healthcare.
Within the body, there are different sources of stem cells - known as the "mother" or "master" cells capable of differentiating into virtually any type of cell. It has been documented by several scientific publications that stem cells may differentiate into a specific cell or tissue type. This suggests the possibility of developing an effective treatment for Alzheimer's Disease. While a treatment remains elusive, this approach may help in addressing memory loss, speech impairments, mood disturbances, and other symptoms of Alzheimer's disease. This novel approach offers great promise to nearly 6 million Americans currently suffering from this disorder.